Startseite Analysis of expression and prognosis of KLK7 in ovarian cancer
Artikel Open Access

Analysis of expression and prognosis of KLK7 in ovarian cancer

  • Erhua Chen , Huifang Zhu , Yue Yang , Ling Wang , Jianhua Zhang , Yonghong Han und Xiang Liu EMAIL logo
Veröffentlicht/Copyright: 30. September 2020

Abstract

Background

Ovarian cancer is one of the common malignant tumors in female reproductive organs. Kallikrein-related peptidase (KLK) 7 is a secreted serine peptidase that is related to different cancer. To investigate the expression and significance of KLK7 in ovarian cancer.

Materials and methods

The expression of KLK7 in human ovarian cancer was evaluated by Oncomine and Cancer Cell Line Encyclopedia database. Then the co-expression genes relevant to the KLK7 gene were analyzed by the Pearson correlation test. Finally, the impact of KLK7 on clinical prognosis was investigated in distinct subtypes of ovarian cancer patients by UALCAN database and Kaplan–Meier plotter database.

Results

It was found that the expression of KLK7 was higher in ovarian cancer compared with other types of cancer, such as gastric cancer and pancreatic cancer. The expression of KLK7 was found to be increased in four various ovarian cancer data sets compared with the healthy tissues. In addition, upregulation of KLK7 expression was associated with age and cancer stage. Moreover, survival analysis revealed that higher KLK7 expression was negatively associated with progression-free survival.

Conclusion

Knowledge of the expression of KLK7 may be useful for better understanding the outcome in ovarian cancer patients.

1 Introduction

Ovarian cancer is the highest mortality of gynecologic malignancy, and it carries a lifetime risk of approximately 2% for women [1]. As ovarian cancer is usually detected in advanced stages, it has poor prognosis even with many treatment options until now [2]. Increasing evidence has suggested that those diagnosed with early stage ovarian cancer may achieve a cure with adjuvant treatment [3]. Therefore, exploring a promising novel biomarker to improve the survival rate of ovarian cancer patients is urgent.

To date, 15 kallikrein-related peptidases (KLKs) family genes are found in the human genome. All of them take part in apoptosis, digestive system enzyme activation and coagulation–fibrinolysis [4]. KLK7 is also known as human stratum corneum chymotryptic enzyme because of its early detection in human skin [5]. In breast cancer, KLK7 was significantly downregulated in the sera of breast cancer and benign breast disease patients, implying a role in the pathogenesis of infiltrating ductal carcinoma [6]. It has been reported that KLK7 and KLK10 are two of the most upregulated genes in papillary thyroid carcinoma, which are involved in cell adhesion and extracellular matrix remodeling [7]. The overexpression of KLK7 can increase the proliferation abilities and promote migration and invasive behavior in pancreatic cancer cells [8]. Wang et al. [9] identify the KLK4–7 genes exert key modulatory effects on some other cancer-related genes at the mRNA and proteins in ovarian cancer cells and tissues. KLK7 secreted in the ovarian cancer microenvironment could in turn accelerate cancer progression [10]. However, little is known about the expression and prognostic role of KLK7 in ovarian cancer.

In our study, Oncomine has been systematically employed to explore the association of KLK7 mRNA expression with ovarian cancer patients. Meanwhile, the correlation of gene and the clinical value of KLK7 were shown by UALCAN database. Survival analysis of KLK7 was achieved based on Kaplan–Meier plotter.

2 Materials and methods

2.1 Oncomine analysis

The Oncomine is a public cancer database (www.oncomine.org) for filtering and missing data in our needs. In this study, we set the screening criteria as follows: “Cancer Type: Ovarian cancer;” “Gene: KLK7;” “Data Type: mRNA,” “Different analysis: cancer vs. normal.” We defined the cutoff as 0.01 and 1.5 for p values and fold changes, respectively, to exam the mRNA expression status of KLK7 in different cancer types.

2.2 Cancer cell line encyclopedia (CCLE) database

The CCLE database provides public access to genomic data, analysis and visualization for cell lines. The KLK7’s expression in different cell lines is verified by CCLE database.

2.3 UALCAN database

UALCAN is an interactive web resource based on level 3 RNA-seq and clinical data of 31 cancer types. We analyzed the expression profiles of KLK7 in normal and ovarian serous cystadenocarcinoma samples based on clinicopathologic parameters, such as cancer stage, age, race and tumor grade.

2.4 The Kaplan–Meier plotter

Kaplan–Meier plotter database was used to evaluate the prognostic significance of KLK7 mRNA expression, which provided the data on survival and gene expression. All patient were divided into two groups, according to the median expression (high and low expression), to analyze the overall survival (OS) and progression-free survival (PFS) by calculating the hazard ratio (HR), 95% confidence intervals (95% CI) and log rank p value.

3 Results

3.1 The mRNA expression levels of KLK7 in human cancers

To compare the mRNA expression difference of KLK7 between tumor and normal tissues in multiple cancers, we used the Oncomine database. As shown in Figure 1, a total of 310 analyses were included for KLK7. The KLK7 mRNA expression was upregulated in 23 studies and downregulated in 35 studies. The KLK7 expression showed upregulated in cancer tissues compared to that in normal tissues.

Figure 1 Transcriptional levels of KLK7 in different types of cancers (ONCOMINE).
Figure 1

Transcriptional levels of KLK7 in different types of cancers (ONCOMINE).

3.2 The expression level of KLK7 mRNA in human ovarian cancer

As shown in Figure 2a–d, KLK7 was found to be increased in four various cancer data sets compared with healthy tissues including ovarian serous adenocarcinoma [11] and ovarian endometrioid adenocarcinoma [12,13].

Figure 2 (a–d) Expression of KLK7 in in four various cancer data sets, (e) comparison of KLK7 across four analyses.
Figure 2

(a–d) Expression of KLK7 in in four various cancer data sets, (e) comparison of KLK7 across four analyses.

A meta-analysis of the results of these four studies was studied. The KLK7 gene was ranked as 948.0 in all expressed genes, which means that KLK7 mRNA expression was significantly increased in two types of ovarian cancer (Figure 2e). Moreover, CCLE database analysis revealed that the mRNA expression levels of KLK7 in ovarian cancer compared with the other cancer cells. The mRNA expression of KLK7 ranks fourth highest in breast cancer and this is based on Affy gene chip data (Figure 3a). The mRNA expression of KLK7 ranks fifth highest in different tumor cell lines RNA-seq data, which is behind that of upper aerodigestive tract, bile duct, esophagus and colorectal (Figure 3b).

Figure 3 (a) Expression of KLK7 based on Affy gene chip data, (b) expression of KLK7 based on RNA-seq data.
Figure 3

(a) Expression of KLK7 based on Affy gene chip data, (b) expression of KLK7 based on RNA-seq data.

3.3 Expression correlation analysis of KLK7 in ovarian cancer

We selected top two genes (KLK8 and SUPT3H) that most positively or negatively correlated with KLK7 to analysis. The klk8 gene expression level was positively correlated with the KLK7 expression with a Pearson CC value of 0.6 (Figure 4a). We observed a negative correlation between KLK7 and SUPT3H expressions with a Pearson CC value of 0.36 (Figure 4b).

Figure 4 Correlation of KLK8, SUPT3H and CHEK1 gene expression in ovarian cancer. (a) Gene expression correlation between KLK7 and KLK8 in OV, (b) gene expression correlation between KLK7 and SUPT3H in OV.
Figure 4

Correlation of KLK8, SUPT3H and CHEK1 gene expression in ovarian cancer. (a) Gene expression correlation between KLK7 and KLK8 in OV, (b) gene expression correlation between KLK7 and SUPT3H in OV.

3.4 Association between KLK7 gene expression and clinical pathological parameters in patients with ovarian cancer

We next concentrated on the detection of KLK7 expression in normal and ovarian serous cystadenocarcinoma samples using UALCAN database. As shown in Figure 5, our analytical mining of the UALCAN database indicated that the expression level of KLK7 was higher in stage 4 compared with stages 2 and 3 of ovarian serous cystadenocarcinoma (P < 0.05) for cancer stages. Besides, KLK7 was downregulated in the age-group 81–100 years compared with those in the age-group 41–60 years (P < 0.05). Unfortunately, no significant difference was observed in the expression of the patients’ race and cancer grade.

Figure 5 The relative expression of KLK7 in ovarian cancer. (a) Expression of KLK7 in OV based n individual cancer stages, (b) expression of KLK7 in OV based on patient's race, (c) expression of KLK7 in OV based on patient's age, (d) expression of KLK7 in OV based on tumor grade.
Figure 5

The relative expression of KLK7 in ovarian cancer. (a) Expression of KLK7 in OV based n individual cancer stages, (b) expression of KLK7 in OV based on patient's race, (c) expression of KLK7 in OV based on patient's age, (d) expression of KLK7 in OV based on tumor grade.

3.5 KLK7 expression was correlated with the survival of ovarian cancer

To further assess the prognostic value of KLK7 in ovarian cancer, the KLK7 mRNA expression was evaluated; the Affymetrix ID was 239381_at KLK7. High KLK7 mRNA expression indicated unfavorable PFS for all patients with ovarian cancer (HR, 1.67; 95% CI, 1.38–2.02; P = 1.3 × 10−07; Figure 6a), patients with serous ovarian cancer (HR, 1.43; 95% CI, 1.16–1.77; P = 0.00084; Figure 6b) and patients with endometrioid ovarian cancer (HR, 5.05; 95% CI, 1.74–14.65; P = 0.00095; Figure 6c). KLK7 exhibited no association with OS in patients with serous ovarian cancer (Figure 7a), serous ovarian cancer (Figure 7b) and endometrioid ovarian cancer (Figure 7c). Although KLK7 expression was not significantly correlated with poor OS, the higher expression of KLK7 in all patients with ovarian cancers is significantly correlated with better PFS (P < 0.05).

Figure 6 Prognostic value of KLK7 expression for OS of patients with ovarian cancer based on the Kaplan–Meier plotter. (a) All KLK7 (239381_at), (b) serous KLK7 (239381_at), (c) endometrioid KLK7 (239381_at).
Figure 6

Prognostic value of KLK7 expression for OS of patients with ovarian cancer based on the Kaplan–Meier plotter. (a) All KLK7 (239381_at), (b) serous KLK7 (239381_at), (c) endometrioid KLK7 (239381_at).

Figure 7 Prognostic value of KLK7 expression for PFS in patients with ovarian cancer based on the Kaplan–Meier plotter. (a) All KLK7 (239381_at), (b) serous KLK7 (239381_at), (c) endometriod KLK7 (239381_at).
Figure 7

Prognostic value of KLK7 expression for PFS in patients with ovarian cancer based on the Kaplan–Meier plotter. (a) All KLK7 (239381_at), (b) serous KLK7 (239381_at), (c) endometriod KLK7 (239381_at).

4 Discussion

Most ovarian cancer patients cannot be cured completely, even with the combination of cytoreductive surgery and chemotherapy drugs [14]. Based on tissue analysis, KLK7 was found in both stromal and tumor cells, whose expression was higher in tumor cells [15,16]. Studies have found that KLK7 increases the expression of integrity adhesion receptors and both forms of the produced serine proteases (KLK7 and the nonproteolytic form) work in ovarian cancer peritoneal invasion [17]. Although some other studies have indicated that different members of KLK family associated with specific cancers and KLK7 as preferred targets for inhibition of ovarian cancer, the distinct role of KLK7 remains to be elucidated [18,19]. In our study, the expression and prognostic of KLK7 were systematically identified by several online databases.

Many studies have reported that KLK7 is overexpressed in healthy tissue than in tumors of ovarian cancer patients and have linked with the some other diseases [20,21] We first systematically analyzed the expression of KLK7 in different cancers using ONCOMINE, and our results confirmed that KLK7 was overexpressed in ovarian cancer, colorectal cancer and gastric cancer. Subsequently, our analysis suggested that high expression of KLK7 in ovarian cancer compared to normal controls among four data sets (Figure 2a–d). By the comparison of KLK7 expression in four data sets, meta-analysis demonstrated that KLK7 was significantly increased in two types of ovarian cancer, namely, ovarian serous adenocarcinoma and ovarian endometrioid adenocarcinoma (Figure 2e). Additionally, KLK7 was also highly expressed in human ovarian cancer cell lines, as implicated by CCLE database, supporting the critical role of KLK7 in ovarian cancer initiation or progression (Figure 3a and b).

Tamir et al. [22] suggested that KLK7 mRNA and protein overexpression are directly associated with early stage ovarian carcinomas and can be measured in patient tissue and serum samples. Further, Kyriakopoulou et al. [23] reported overexpressed KLK7 in ovarian cancer had an association with those high tumor grade diseases. In our report, we demonstrated that the expression of KLK7 was higher in a range of 41–60 years cancer stage. Previous studies indicated that high KLK7 expression was significantly associated with prolonged OS and PFS [24]. Then we evaluated whether overexpression of KLK7 was associated with clinicopathological features and survival outcomes by Kaplan–Meier plotter database. In contrast to this result, our finding revealed that overexpressed KLK7 was significantly associated with worse FPS in ovarian cancer.

Our study has certain limitations. It was only analyzed by online databases, and experimental or clinical validation would be needed to confirm the expression of KLK7 in ovarian cancer. More investigations should focus on a functional characterization and molecular mechanisms of the upregulated or downregulated factors in other significant KLK7 family members that are involved in KLK-mediated functions. In addition, we did not assess the potential diagnostic and therapeutic effect and explore whether it can be used as diagnostic markers or treatment. Taken together, we identified KLK7 gene is potentially involved in prognosis through bioinformatics analysis. KLK7 gene should be considered as potential prognostic biomarker for a better understanding of ovarian cancer progression and therapy.


Erhua Chen and Huifang Zhu have made an equal contribution to this work.


  1. Conflict of interest: Authors state no conflict of interest.

References

[1] Carlo VL. Ovarian cancer: epidemiology and risk factors. Eur J Cancer Prev. 2017;26:55–62.10.1097/CEJ.0000000000000217Suche in Google Scholar

[2] Pal P, Hales K, Petrik J, Hales B. Pro-apoptotic and anti-angiogenic actions of 2-methoxyestradiol and docosahexaenoic acid, the biologically derived active compounds from flaxseed diet, in preventing ovarian cancer. J Ovarian Res. 2019;12:49.10.1186/s13048-019-0523-3Suche in Google Scholar

[3] Suhburgmann E, Alavi M. Detection of early stage ovarian cancer in a large community cohort. Cancer Med. 2019;8:7133–40.10.1002/cam4.2522Suche in Google Scholar

[4] Prassas I, Eissa A, Poda G, Diamandis EP. Unleashing the therapeutic potential of human kallikrein-related serine proteases. Nat Rev Drug Discovery. 2015;14:183–202.10.1038/nrd4534Suche in Google Scholar

[5] Hansson L, Stromqvist M, Backman A, Wallbrandt P, Carlstein A, Egelrud T. Cloning, expression, and characterization of stratum corneum chymotryptic enzyme. A skin-specific human serine proteinase. J Biol Chem. 1994;269:19420–6.10.1016/S0021-9258(17)32185-3Suche in Google Scholar

[6] Ejaz S, Nasim F, Ashraf M, Ahmad G. Down-regulation of hK7 in the sera of breast cancer and benign breast disease patients. Heliyon. 2017;3:e00356.10.1016/j.heliyon.2017.e00356Suche in Google Scholar PubMed PubMed Central

[7] Reyes I, Reyes N, Suriano R, Iacob C, Suslina N, Policastro A, et al. Gene expression profiling identifies potential molecular markers of papillary thyroid carcinoma. Crim Behav Ment Health. 2019;24:71–83.10.3233/CBM-181758Suche in Google Scholar PubMed

[8] Zheng SL, Feng MY, Yang G, Xiong GB, Zheng LF, Zhang T, et al. The expression of KLK7 in pancreatic cancer and the effects on the biological behavior of pancreatic cancer cells. Chin J Surg. 2018;56:391–7.Suche in Google Scholar

[9] Wang P, Magdolen V, Seidl C, Dorn J, Drecoll E, Kotzsch M, et al. Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer. Br J Cancer. 2018;119:1–9.10.1038/s41416-018-0260-1Suche in Google Scholar PubMed PubMed Central

[10] Silva LM, Kryza T, Stoll T, Hoogland C, Dong Y, Stephens C, et al. Integration of two in-depth quantitative proteomics approaches determines the kallikrein-related peptidase 7 (KLK7) degradome in ovarian cancer cell secretome. Mol Cell Proteom. 2019;18:818–36.10.1074/mcp.RA118.001304Suche in Google Scholar PubMed PubMed Central

[11] Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004;10:3291–300.10.1158/1078-0432.CCR-03-0409Suche in Google Scholar PubMed

[12] Yoshihara K, Tajima A, Komata D, Yamamoto T, Kodama S, Fujiwara H, et al. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis. Cancer Sci. 2009;100:1421–8.10.1111/j.1349-7006.2009.01204.xSuche in Google Scholar

[13] Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res. 2006;66:1354–62.10.1158/0008-5472.CAN-05-3694Suche in Google Scholar

[14] Mcguire WP, Hoskins WJ, Brady MF, Kucera PR, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage iii and stage iv ovarian cancer. N Engl J Med. 1996;334:1–6.10.1056/NEJM199601043340101Suche in Google Scholar

[15] Dorn J, Gkazepis A, Kotzsch M, Kremer M, Propping C, Mayer K, et al. Clinical value of protein expression of kallikrein-related peptidase 7 (klk7) in ovarian cancer. Biol Chem. 2014;395:95–107.10.1515/hsz-2013-0172Suche in Google Scholar PubMed

[16] Dorn J, Yassouridis A, Walch A, Diamandis EP, Schmitt M, Kiechle M, et al. Assessment of kallikrein-related peptidase 5 (klk5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome. Am J Cancer Res. 2015;6:61.Suche in Google Scholar

[17] Dong Y, Tan OL, Loessner D, Stephens C, Walpole C, Boyle GM, et al. Kallikrein-related peptidase 7 promotes multicellular aggregation via the? 5? 1 integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma. Cancer Res. 2010;70:2624–33.10.1158/0008-5472.CAN-09-3415Suche in Google Scholar

[18] Daniela L, Peter G, Sarah P, Johanna F, Holger B, Clements JA, et al. Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancer. Expert Opin Ther Targets. 2018;22:745–63.10.1080/14728222.2018.1512587Suche in Google Scholar

[19] Dong Y, Kaushal A, Brattsand M, Nicklin J, Clements JA. Differential splicing of klk5 and klk7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin Cancer Res an Off J Am Assoc Cancer Res. 2003;9:1710–20.Suche in Google Scholar

[20] Girgis A, Bui A, White NM, Yousef GM. Integrated genomic characterization of the Kallikrein gene locus in cancer. Anticancer Res. 2012;32:957–63.Suche in Google Scholar

[21] Psyrri A, Kountourakis P, Scorilas A, Markakis S, Camp R, Kowalski D, et al. Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. Ann Oncol. 2008;19:1271–7.10.1093/annonc/mdn035Suche in Google Scholar

[22] Tamir A, Jag U, Sarojini S, Schindewolf C, Tanaka T, Gharbaran R, et al. Kallikrein family proteases klk6 and klk7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes. J Ovarian Res. 2014;7:109.10.1186/s13048-014-0109-zSuche in Google Scholar

[23] Kyriakopoulou LG, Yousef GM, Scorilas A, Katsaros D, Massobrio M, Fracchioli S, et al. Prognostic value of quantitatively assessed klk7 expression in ovarian cancer. Clin Biochem. 2003;36:135–43.10.1016/S0009-9120(02)00446-0Suche in Google Scholar

[24] Dorn J, Gkazepis A, Kotzsch M, Kremer M, Propping C, Mayer K, et al. Clinical value of protein expression of kallikrein-related peptidase 7 (klk7) in ovarian cancer. Biol Chem. 2014;395:95–107.10.1515/hsz-2013-0172Suche in Google Scholar

Received: 2020-04-06
Revised: 2020-08-11
Accepted: 2020-08-23
Published Online: 2020-09-30

© 2020 Erhua Chen et al., published by De Gruyter

This work is licensed under the Creative Commons Attribution 4.0 International License.

Artikel in diesem Heft

  1. Research Article
  2. MicroRNA-451b participates in coronary heart disease by targeting VEGFA
  3. Case Report
  4. A combination therapy for Kawasaki disease with severe complications: a case report
  5. Vitamin E for prevention of biofilm-caused Healthcare-associated infections
  6. Research Article
  7. Differential diagnosis: retroperitoneal fibrosis and oncological diseases
  8. Optimization of the Convolutional Neural Networks for Automatic Detection of Skin Cancer
  9. NEAT1 promotes LPS-induced inflammatory injury in macrophages by regulating miR-17-5p/TLR4
  10. Plasma matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 as prognostic biomarkers in critically ill patients
  11. Effects of extracorporeal magnetic stimulation in fecal incontinence
  12. Case Report
  13. Mixed germ cell tumor of the endometrium: a case report and literature review
  14. Bowel perforation after ventriculoperitoneal-shunt placement: case report and review of the literature
  15. Research Article
  16. Prognostic value of lncRNA HOTAIR in colorectal cancer : a meta-analysis
  17. Case Report
  18. Treatment of insulinomas by laparoscopic radiofrequency ablation: case reports and literature review
  19. Research Article
  20. The characteristics and nomogram for primary lung papillary adenocarcinoma
  21. Undiagnosed pheochromocytoma presenting as a pancreatic tumor: A case report
  22. Bioinformatics Analysis of the Expression of ATP binding cassette subfamily C member 3 (ABCC3) in Human Glioma
  23. Diagnostic value of recombinant heparin-binding hemagglutinin adhesin protein in spinal tuberculosis
  24. Primary cutaneous DLBCL non-GCB type: challenges of a rare case
  25. LINC00152 knock-down suppresses esophageal cancer by EGFR signaling pathway
  26. Case Report
  27. Life-threatening anaemia in patient with hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)
  28. Research Article
  29. QTc interval predicts disturbed circadian blood pressure variation
  30. Shoulder ultrasound in the diagnosis of the suprascapular neuropathy in athletes
  31. The number of negative lymph nodes is positively associated with survival in esophageal squamous cell carcinoma patients in China
  32. Differentiation of pontine infarction by size
  33. RAF1 expression is correlated with HAF, a parameter of liver computed tomographic perfusion, and may predict the early therapeutic response to sorafenib in advanced hepatocellular carcinoma patients
  34. LncRNA ZEB1-AS1 regulates colorectal cancer cells by miR-205/YAP1 axis
  35. Tissue coagulation in laser hemorrhoidoplasty – an experimental study
  36. Classification of pathological types of lung cancer from CT images by deep residual neural networks with transfer learning strategy
  37. Enhanced Recovery after Surgery for Lung Cancer Patients
  38. Case Report
  39. Streptococcus pneumoniae-associated thrombotic microangiopathy in an immunosuppressed adult
  40. Research Article
  41. The characterization of Enterococcus genus: resistance mechanisms and inflammatory bowel disease
  42. Case Report
  43. Inflammatory fibroid polyp: an unusual cause of abdominal pain in the upper gastrointestinal tract A case report
  44. Research Article
  45. microRNA-204-5p participates in atherosclerosis via targeting MMP-9
  46. LncRNA LINC00152 promotes laryngeal cancer progression by sponging miR-613
  47. Can keratin scaffolds be used for creating three-dimensional cell cultures?
  48. miRNA-186 improves sepsis induced renal injury via PTEN/PI3K/AKT/P53 pathway
  49. Case Report
  50. Delayed bowel perforation after routine distal loopogram prior to ileostomy closure
  51. Research Article
  52. Diagnostic accuracy of MALDI-TOF mass spectrometry for the direct identification of clinical pathogens from urine
  53. The R219K polymorphism of the ATP binding cassette subfamily A member 1 gene and susceptibility to ischemic stroke in Chinese population
  54. miR-92 regulates the proliferation, migration, invasion and apoptosis of glioma cells by targeting neogenin
  55. Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma
  56. NF2 inhibits proliferation and cancer stemness in breast cancer
  57. Body composition indices and cardiovascular risk in type 2 diabetes. CV biomarkers are not related to body composition
  58. S100A6 promotes proliferation and migration of HepG2 cells via increased ubiquitin-dependent degradation of p53
  59. Review Article
  60. Focus on localized laryngeal amyloidosis: management of five cases
  61. Research Article
  62. NEAT1 aggravates sepsis-induced acute kidney injury by sponging miR-22-3p
  63. Pericentric inversion in chromosome 1 and male infertility
  64. Increased atherogenic index in the general hearing loss population
  65. Prognostic role of SIRT6 in gastrointestinal cancers: a meta-analysis
  66. The complexity of molecular processes in osteoarthritis of the knee joint
  67. Interleukin-6 gene −572 G > C polymorphism and myocardial infarction risk
  68. Case Report
  69. Severe anaphylactic reaction to cisatracurium during anesthesia with cross-reactivity to atracurium
  70. Research Article
  71. Rehabilitation training improves nerve injuries by affecting Notch1 and SYN
  72. Case Report
  73. Myocardial amyloidosis following multiple myeloma in a 38-year-old female patient: A case report
  74. Research Article
  75. Identification of the hub genes RUNX2 and FN1 in gastric cancer
  76. miR-101-3p sensitizes non-small cell lung cancer cells to irradiation
  77. Distinct functions and prognostic values of RORs in gastric cancer
  78. Clinical impact of post-mortem genetic testing in cardiac death and cardiomyopathy
  79. Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis
  80. Review Article
  81. The role of osteoprotegerin in the development, progression and management of abdominal aortic aneurysms
  82. Research Article
  83. Identification of key microRNAs of plasma extracellular vesicles and their diagnostic and prognostic significance in melanoma
  84. miR-30a-3p participates in the development of asthma by targeting CCR3
  85. microRNA-491-5p protects against atherosclerosis by targeting matrix metallopeptidase-9
  86. Bladder-embedded ectopic intrauterine device with calculus
  87. Case Report
  88. Mycobacterial identification on homogenised biopsy facilitates the early diagnosis and treatment of laryngeal tuberculosis
  89. Research Article
  90. The will of young minors in the terminal stage of sickness: A case report
  91. Extended perfusion protocol for MS lesion quantification
  92. Identification of four genes associated with cutaneous metastatic melanoma
  93. Case Report
  94. Thalidomide-induced serious RR interval prolongation (longest interval >5.0 s) in multiple myeloma patient with rectal cancer: A case report
  95. Research Article
  96. Voluntary exercise and cardiac remodeling in a myocardial infarction model
  97. Electromyography as an intraoperative test to assess the quality of nerve anastomosis – experimental study on rats
  98. Case Report
  99. CT findings of severe novel coronavirus disease (COVID-19): A case report of Heilongjiang Province, China
  100. Commentary
  101. Directed differentiation into insulin-producing cells using microRNA manipulation
  102. Research Article
  103. Culture-negative infective endocarditis (CNIE): impact on postoperative mortality
  104. Extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome
  105. Plasma microRNAs in human left ventricular reverse remodelling
  106. Bevacizumab for non-small cell lung cancer patients with brain metastasis: A meta-analysis
  107. Risk factors for cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage
  108. Problems and solutions of personal protective equipment doffing in COVID-19
  109. Evaluation of COVID-19 based on ACE2 expression in normal and cancer patients
  110. Review Article
  111. Gastroenterological complications in kidney transplant patients
  112. Research Article
  113. CXCL13 concentration in latent syphilis patients with treatment failure
  114. A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction
  115. Case Report
  116. Clinicopathological analysis of composite lymphoma: A two-case report and literature review
  117. Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment
  118. Research Article
  119. Inhibition of vitamin D analog eldecalcitol on hepatoma in vitro and in vivo
  120. CCTs as new biomarkers for the prognosis of head and neck squamous cancer
  121. Effect of glucagon-like peptide-1 receptor agonists on adipokine level of nonalcoholic fatty liver disease in rats fed high-fat diet
  122. 72 hour Holter monitoring, 7 day Holter monitoring, and 30 day intermittent patient-activated heart rhythm recording in detecting arrhythmias in cryptogenic stroke patients free from arrhythmia in a screening 24 h Holter
  123. FOXK2 downregulation suppresses EMT in hepatocellular carcinoma
  124. Case Report
  125. Total parenteral nutrition-induced Wernicke’s encephalopathy after oncologic gastrointestinal surgery
  126. Research Article
  127. Clinical prediction for outcomes of patients with acute-on-chronic liver failure associated with HBV infection: A new model establishment
  128. Case Report
  129. Combination of chest CT and clinical features for diagnosis of 2019 novel coronavirus pneumonia
  130. Research Article
  131. Clinical significance and potential mechanisms of miR-223-3p and miR-204-5p in squamous cell carcinoma of head and neck: a study based on TCGA and GEO
  132. Review Article
  133. Hemoperitoneum caused by spontaneous rupture of hepatocellular carcinoma in noncirrhotic liver. A case report and systematic review
  134. Research Article
  135. Voltage-dependent anion channels mediated apoptosis in refractory epilepsy
  136. Prognostic factors in stage I gastric cancer: A retrospective analysis
  137. Circulating irisin is linked to bone mineral density in geriatric Chinese men
  138. Case Report
  139. A family study of congenital dysfibrinogenemia caused by a novel mutation in the FGA gene: A case report
  140. Research Article
  141. CBCT for estimation of the cemento-enamel junction and crestal bone of anterior teeth
  142. Case Report
  143. Successful de-escalation antibiotic therapy using cephamycins for sepsis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia: A sequential 25-case series
  144. Research Article
  145. Influence factors of extra-articular manifestations in rheumatoid arthritis
  146. Assessment of knowledge of use of electronic cigarette and its harmful effects among young adults
  147. Predictive factors of progression to severe COVID-19
  148. Procedural sedation and analgesia for percutaneous trans-hepatic biliary drainage: Randomized clinical trial for comparison of two different concepts
  149. Acute chemoradiotherapy toxicity in cervical cancer patients
  150. IGF-1 regulates the growth of fibroblasts and extracellular matrix deposition in pelvic organ prolapse
  151. NANOG regulates the proliferation of PCSCs via the TGF-β1/SMAD pathway
  152. An immune-relevant signature of nine genes as a prognostic biomarker in patients with gastric carcinoma
  153. Computer-aided diagnosis of skin cancer based on soft computing techniques
  154. MiR-1225-5p acts as tumor suppressor in glioblastoma via targeting FNDC3B
  155. miR-300/FA2H affects gastric cancer cell proliferation and apoptosis
  156. Hybrid treatment of fibroadipose vascular anomaly: A case report
  157. Surgical treatment for common hepatic aneurysm. Original one-step technique
  158. Neuropsychiatric symptoms, quality of life and caregivers’ burden in dementia
  159. Predictor of postoperative dyspnea for Pierre Robin Sequence infants
  160. Long non-coding RNA FOXD2-AS1 promotes cell proliferation, metastasis and EMT in glioma by sponging miR-506-5p
  161. Analysis of expression and prognosis of KLK7 in ovarian cancer
  162. Circular RNA circ_SETD2 represses breast cancer progression via modulating the miR-155-5p/SCUBE2 axis
  163. Glial cell induced neural differentiation of bone marrow stromal cells
  164. Case Report
  165. Moraxella lacunata infection accompanied by acute glomerulonephritis
  166. Research Article
  167. Diagnosis of complication in lung transplantation by TBLB + ROSE + mNGS
  168. Case Report
  169. Endometrial cancer in a renal transplant recipient: A case report
  170. Research Article
  171. Downregulation of lncRNA FGF12-AS2 suppresses the tumorigenesis of NSCLC via sponging miR-188-3p
  172. Case Report
  173. Splenic abscess caused by Streptococcus anginosus bacteremia secondary to urinary tract infection: a case report and literature review
  174. Research Article
  175. Advances in the role of miRNAs in the occurrence and development of osteosarcoma
  176. Rheumatoid arthritis increases the risk of pleural empyema
  177. Effect of miRNA-200b on the proliferation and apoptosis of cervical cancer cells by targeting RhoA
  178. LncRNA NEAT1 promotes gastric cancer progression via miR-1294/AKT1 axis
  179. Key pathways in prostate cancer with SPOP mutation identified by bioinformatic analysis
  180. Comparison of low-molecular-weight heparins in thromboprophylaxis of major orthopaedic surgery – randomized, prospective pilot study
  181. Case Report
  182. A case of SLE with COVID-19 and multiple infections
  183. Research Article
  184. Circular RNA hsa_circ_0007121 regulates proliferation, migration, invasion, and epithelial–mesenchymal transition of trophoblast cells by miR-182-5p/PGF axis in preeclampsia
  185. SRPX2 boosts pancreatic cancer chemoresistance by activating PI3K/AKT axis
  186. Case Report
  187. A case report of cervical pregnancy after in vitro fertilization complicated by tuberculosis and a literature review
  188. Review Article
  189. Serrated lesions of the colon and rectum: Emergent epidemiological data and molecular pathways
  190. Research Article
  191. Biological properties and therapeutic effects of plant-derived nanovesicles
  192. Case Report
  193. Clinical characterization of chromosome 5q21.1–21.3 microduplication: A case report
  194. Research Article
  195. Serum calcium levels correlates with coronary artery disease outcomes
  196. Rapunzel syndrome with cholangitis and pancreatitis – A rare case report
  197. Review Article
  198. A review of current progress in triple-negative breast cancer therapy
  199. Case Report
  200. Peritoneal-cutaneous fistula successfully treated at home: A case report and literature review
  201. Research Article
  202. Trim24 prompts tumor progression via inducing EMT in renal cell carcinoma
  203. Degradation of connexin 50 protein causes waterclefts in human lens
  204. GABRD promotes progression and predicts poor prognosis in colorectal cancer
  205. The lncRNA UBE2R2-AS1 suppresses cervical cancer cell growth in vitro
  206. LncRNA FOXD3-AS1/miR-135a-5p function in nasopharyngeal carcinoma cells
  207. MicroRNA-182-5p relieves murine allergic rhinitis via TLR4/NF-κB pathway
Heruntergeladen am 14.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/med-2020-0139/html
Button zum nach oben scrollen